Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PGNY

Progyny Inc

May 03 • 04:00PM ET

31.72

Dollar change -0.35
Percentage change -1.09	%

Healthcare • Health Information Services • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB IWM VXF VBK IWO IJK SCHA VTWO

Index	RUT	P/E	51.43	EPS (ttm)	0.62	Insider Own	13.90%	Shs Outstand	95.73M	Perf Week	-1.00%
Market Cap	3.06B	Forward P/E	31.79	EPS next Y	1.00	Insider Trans	-4.87%	Shs Float	83.09M	Perf Month	-10.65%
Income	62.04M	PEG	3.65	EPS next Q	0.13	Inst Own	87.62%	Short Float	7.95%	Perf Quarter	-18.85%
Sales	1.09B	P/S	2.81	EPS this Y	12.19%	Inst Trans	-1.63%	Short Ratio	7.60	Perf Half Y	4.24%
Book/sh	5.78	P/B	5.49	EPS next Y	43.46%	ROA	9.48%	Short Interest	6.60M	Perf Year	-6.98%
Cash/sh	3.85	P/C	8.25	EPS next 5Y	14.10%	ROE	13.34%	52W Range	29.44 - 44.95	Perf YTD	-14.69%
Dividend Est.	-	P/FCF	16.53	EPS past 5Y	-	ROI	10.87%	52W High	-29.43%	Beta	1.51
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	61.75%	Gross Margin	21.94%	52W Low	7.74%	ATR (14)	0.98
Dividend Ex-Date	-	Current Ratio	3.44	EPS Y/Y TTM	98.39%	Oper. Margin	5.71%	RSI (14)	34.35	Volatility	3.05% 2.55%
Employees	566	Debt/Eq	0.04	Sales Y/Y TTM	38.34%	Profit Margin	5.70%	Recom	1.10	Target Price	47.10
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	292.08%	Payout	0.00%	Rel Volume	0.87	Prev Close	32.07
Sales Surprise	-1.51%	EPS Surprise	20.93%	Sales Q/Q	25.95%	Earnings	May 09 AMC	Avg Volume	869.15K	Price	31.72
SMA20	-4.93%	SMA50	-9.96%	SMA200	-11.72%	Trades		Volume	760,420	Change	-1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-24	Initiated	Leerink Partners	Outperform	$49
Jan-03-24	Initiated	Barclays	Overweight	$48
Sep-27-23	Initiated	Canaccord Genuity	Buy	$46
May-22-23	Initiated	BTIG Research	Buy	$50
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight	$44
Jan-05-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$34
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$55
Sep-07-22	Initiated	Truist	Buy	$56
Dec-02-21	Initiated	Jefferies	Buy	$60
Nov-22-21	Downgrade	Citigroup	Buy → Neutral	$60 → $64
Sep-30-21	Initiated	Berenberg	Buy	$81
Aug-12-21	Initiated	Barclays	Overweight	$64
Jun-02-21	Downgrade	Guggenheim	Buy → Neutral
Apr-29-21	Resumed	JP Morgan	Overweight	$65
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy	$53
Jul-01-20	Initiated	SVB Leerink	Outperform	$35
Jun-02-20	Initiated	Guggenheim	Buy	$30
Nov-19-19	Initiated	SVB Leerink	Outperform	$28
Nov-19-19	Initiated	Piper Jaffray	Overweight	$33
Nov-19-19	Initiated	JP Morgan	Overweight	$26

Show Previous Ratings

May-03-24 02:48AM	Insider Sale: President Michael Sturmer Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Apr-25-24 02:00PM	Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report (GlobeNewswire)
Apr-17-24 09:23AM	Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care (GlobeNewswire)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
Apr-04-24 08:59AM	Progyny and RESOLVE to Honor National Infertility Awareness Week with Events Spanning Coast to Coast (GlobeNewswire)
07:01PM	Loading…
Apr-03-24 07:01PM	Insider Sell: President Michael Sturmer Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-30-24 01:30AM	Executive Chairman David Schlanger Sells 71,272 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
01:37AM	Executive Chairman David Schlanger Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-26-24 07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
Mar-18-24 12:00PM	Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-13-24 04:30PM	The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024 (InvestorPlace)
Mar-11-24 12:00PM	Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Feb-29-24 05:48PM	IVF Is Increasingly Big Business. Alabamas Ruling Could Actually Make It Bigger. (Barrons.com) +5.40%
07:30AM	Progyny, Inc. Announces Share Repurchase Program (GlobeNewswire)
10:41AM	Loading…
Feb-28-24 10:41AM	Progyny Stock Falls Sharply After Earnings. What the IVF Ruling Means for It. (Barrons.com) -15.05%
10:15AM	Progyny, Inc. (NASDAQ:PGNY) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:01AM	Progyny Stock Is Falling After Earnings. What the IVF Ruling Means for It. (Barrons.com)
07:19AM	Q4 2023 Progyny Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 05:11PM	Progyny: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	Progyny Inc (PGNY) Surpasses $1 Billion Annual Revenue, Net Income Soars in Q4 (GuruFocus.com)
04:01PM	Progyny, Inc. Announces Fourth Quarter 2023 Results (GlobeNewswire)
Feb-13-24 04:30PM	Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report (GlobeNewswire)
Feb-08-24 03:06AM	Executive Chairman David Schlanger Sells 20,000 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Feb-05-24 11:30PM	Executive Chairman David Schlanger Sells 60,000 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Jan-24-24 01:36PM	3 Cash-Rich Stocks to Buy for Peace of MInd in 2024 (InvestorPlace)
Jan-17-24 09:30AM	Vistia Health selects Progyny as its preferred fertility and family building benefits provider (PR Newswire)
Jan-16-24 06:10PM	3 Mid-Cap Stocks Poised for a Breakout in 2024 (InvestorPlace)
Jan-12-24 09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
05:03AM	Executive Chairman David Schlanger Sells 66,002 Shares of Progyny Inc (GuruFocus.com)
09:01AM	Loading…
Jan-11-24 09:01AM	Progyny Expands its Leadership Team (GlobeNewswire)
Jan-08-24 10:30AM	Progyny, Inc. to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-24 03:12AM	Progyny Inc CFO Mark Livingston Sells 12,368 Shares (GuruFocus.com)
Jan-05-24 03:02AM	Executive Chairman David Schlanger Sells 13,998 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Dec-29-23 09:01PM	Progyny Inc Executive Chairman David Schlanger Sells 156,031 Shares (GuruFocus.com)
Dec-24-23 03:01AM	Executive Chairman David Schlanger Sells 162,906 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Dec-19-23 06:49AM	24 Countries With Biggest Population Decline (Insider Monkey) +5.33%
05:10AM	4 Unstoppable Multibaggers to Buy in 2024 and Hold for the Next Decade (Motley Fool)
Nov-20-23 10:17AM	Does Progyny (PGNY) have a Long Runway for Growth? (Insider Monkey)
Nov-13-23 12:45PM	Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Nov-10-23 12:00PM	Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Nov-09-23 03:52PM	Progyny, Inc. (NASDAQ:PGNY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:58PM	Progyny: Q3 Earnings Snapshot (Associated Press Finance)
04:49PM	Progyny Inc (PGNY) Posts Record Revenue in Q3 2023, Raises Full-Year Guidance (GuruFocus.com)
04:05PM	Progyny, Inc. Announces Third Quarter 2023 Results (GlobeNewswire)
Nov-02-23 06:04AM	The Stage Is Set for a Rally: Canaccord Sees up to 290% Upside for These 3 Stocks (TipRanks)
Nov-01-23 11:27PM	30 Most Fertile Countries in the World Heading into 2024 (Insider Monkey)
10:01AM	Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline (Zacks)
09:00AM	The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant to Help BIPOC Individuals and Couples Expand Their Families (GlobeNewswire)
Oct-31-23 10:01AM	Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline (Zacks)
Oct-27-23 09:45AM	2 Super Stocks That Could Go Parabolic (Motley Fool)
Oct-24-23 02:00PM	Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report (GlobeNewswire)
Oct-10-23 11:34AM	Small Growth Stocks Have Gotten Crushed. Time to Buy. (Barrons.com)
Sep-27-23 10:16AM	3 Growth Stocks to Buy That Could Be Massive Long-Term Winners (Motley Fool)
Sep-26-23 07:35PM	Progyny (PGNY): Unveiling Its True Value (GuruFocus.com)
Sep-01-23 12:45PM	3 Reasons Growth Investors Will Love Progyny (PGNY) (Zacks)
Aug-29-23 10:46AM	Wall Street Loves These 3 Growth Stocks; Should You? (Motley Fool)
Aug-22-23 11:56AM	Progyny Celebrates More Than 30,000 Amazonians Supported on Their Family Building Journeys (GlobeNewswire)
Aug-16-23 12:45PM	Here is Why Growth Investors Should Buy Progyny (PGNY) Now (Zacks)
07:57AM	Heres Why Progyny (PGNY) Outperformed in Q2 (Insider Monkey)
Aug-11-23 12:00PM	Progyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-10-23 06:28AM	TPG GP A, LLC Reduces Stake in Progyny Inc (GuruFocus.com)
Aug-07-23 08:29AM	Fertility benefits management company Progyny expands to offer menopause care (American City Business Journals)
Aug-05-23 09:24AM	Is There Now An Opportunity In Progyny, Inc. (NASDAQ:PGNY)? (Simply Wall St.)
Aug-04-23 09:01AM	Progyny Unveils Nationwide Access to Menopause Care (GlobeNewswire) +6.11%
06:47AM	Q2 2023 Progyny Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 09:00PM	Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:28PM	Progyny: Q2 Earnings Snapshot (AP Finance)
04:01PM	Progyny, Inc. Announces Second Quarter 2023 Results (GlobeNewswire)
Jul-21-23 11:20AM	In their rush to offer fertility benefits, employers could be unwittingly creating a new inequity for LGTBQIA+ employees (Fortune)
Jul-20-23 12:00PM	Progyny, Inc. Announces Details for Its Second Quarter 2023 Results Report (GlobeNewswire)
10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-18-23 11:40AM	MD vs. PGNY: Which Stock Is the Better Value Option? (Zacks)
06:37AM	Progyny (NASDAQ:PGNY) grows 4.8% this week, taking three-year gains to 54% (Simply Wall St.)
Jul-17-23 06:51PM	7 Growth Stocks to Buy to go Beyond the Magnificent 7 (InvestorPlace)
04:37AM	30 Countries With Highest Rates of Population Growth (Insider Monkey)
Jul-11-23 03:00PM	Small Growth Stocks Are Finally Catching Big Tech (Barrons.com)
Jul-10-23 10:00AM	4 Top Stocks to Buy in July and Hold Forever (Motley Fool)
Jul-07-23 12:00PM	What Makes Progyny (PGNY) a New Buy Stock (Zacks)
Jun-29-23 08:30AM	Quantum Health Partners With Progyny To Launch New Family-Building Benefits Offering (Business Wire)
Jun-27-23 01:26PM	Progyny (NASDAQ:PGNY) Is Experiencing Growth In Returns On Capital (Simply Wall St.)
Jun-21-23 08:00PM	PGNY: Lowering target price to $50.00 (Argus Research)
Jun-15-23 09:30AM	These 3 Unique Stocks Have Undeniable Long-Term Upside (Motley Fool)
Jun-14-23 10:02AM	The Best Stocks to Invest $10,000 in Right Now (Motley Fool)
Jun-12-23 09:55AM	Should You Buy Progyny (PGNY) After Golden Cross? (Zacks)
Jun-07-23 07:06AM	Progyny, Inc.'s (NASDAQ:PGNY) Intrinsic Value Is Potentially 99% Above Its Share Price (Simply Wall St.)
Jun-05-23 12:00PM	Progyny, Inc. to Present at Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-24-23 06:51AM	Have $1,000? These 3 Stocks Could Be Bargain Buys for 2023 and Beyond. (Motley Fool)
May-17-23 12:45PM	Looking for a Growth Stock? 3 Reasons Why Progyny (PGNY) is a Solid Choice (Zacks)
12:20PM	Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy? (Zacks)
09:55AM	How Much Upside is Left in Progyny (PGNY)? Wall Street Analysts Think 32.32% (Zacks)
May-09-23 06:49AM	Q1 2023 Progyny Inc Earnings Call (Thomson Reuters StreetEvents) +8.46%
May-08-23 05:35PM	Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:33PM	Progyny: Q1 Earnings Snapshot (AP Finance)
04:03PM	Progyny, Inc. Announces First Quarter 2023 Results (GlobeNewswire)
May-04-23 01:26PM	Declining Stock and Decent Financials: Is The Market Wrong About Progyny, Inc. (NASDAQ:PGNY)? (Simply Wall St.)
May-02-23 12:00PM	Progyny, Inc. to Present at Bank of America Health Care Conference 2023 (GlobeNewswire)
Apr-27-23 05:35AM	4 Growth Stocks to Buy and Hold Forever (Motley Fool)
Apr-26-23 08:00PM	PGNY: Lowering target price to $36.00 (Argus Research)

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm's network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Payson Norman	Director	Nov 23 '24	Sale	56.29	200	11,258	580,656	Nov 26 04:34 PM
Sturmer Michael E	PRESIDENT	May 01 '24	Sale	31.95	4,515	144,254	380,038	May 02 07:05 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Apr 01 '24	Option Exercise	3.95	20,627	81,477	72,875	Apr 03 05:16 PM
Schlanger David J	Executive Chairman	Apr 01 '24	Option Exercise	3.95	1,000	3,950	87,312	Apr 03 05:27 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Apr 01 '24	Sale	37.62	11,165	419,979	50,119	Apr 03 05:16 PM
Sturmer Michael E	PRESIDENT	Apr 01 '24	Sale	37.60	6,395	240,452	384,553	Apr 03 05:23 PM
Schlanger David J	Executive Chairman	Apr 01 '24	Sale	37.52	1,000	37,522	83,631	Apr 03 05:27 PM
Schlanger David J	Executive Chairman	Mar 27 '24	Option Exercise	3.95	71,272	281,845	157,584	Mar 29 07:01 PM
Schlanger David J	Executive Chairman	Mar 27 '24	Sale	37.80	71,272	2,694,267	86,312	Mar 29 07:01 PM
Schlanger David J	Executive Chairman	Mar 26 '24	Option Exercise	3.95	305	1,206	86,617	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 26 '24	Sale	37.50	305	11,439	86,312	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 25 '24	Option Exercise	3.95	2,597	10,270	88,909	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 25 '24	Sale	37.65	2,597	97,778	86,312	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 21 '24	Option Exercise	3.95	5,826	23,039	92,138	Mar 25 06:42 PM
Schlanger David J	Executive Chairman	Mar 21 '24	Sale	37.74	5,826	219,877	86,312	Mar 25 06:42 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Mar 01 '24	Option Exercise	3.95	22,000	86,900	65,647	Mar 05 05:04 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Mar 01 '24	Sale	36.64	12,610	461,977	38,254	Mar 05 05:04 PM
Sturmer Michael E	PRESIDENT	Mar 01 '24	Sale	36.63	11,009	403,260	141,738	Mar 05 04:57 PM
Sturmer Michael E	PRESIDENT	Feb 06 '24	Sale	40.00	2,260	90,400	158,532	Feb 08 06:53 PM
Schlanger David J	Executive Chairman	Feb 05 '24	Option Exercise	3.95	20,000	79,090	106,312	Feb 07 06:38 PM
Schlanger David J	Executive Chairman	Feb 05 '24	Sale	38.50	20,000	769,928	86,312	Feb 07 06:38 PM
Schlanger David J	Executive Chairman	Feb 02 '24	Option Exercise	3.95	30,000	118,635	116,312	Feb 05 06:51 PM
Schlanger David J	Executive Chairman	Feb 02 '24	Sale	38.92	30,000	1,167,490	86,312	Feb 05 06:51 PM
Schlanger David J	Executive Chairman	Feb 01 '24	Option Exercise	3.95	30,000	118,635	116,312	Feb 05 06:51 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Option Exercise	3.95	22,000	86,900	68,871	Feb 05 07:03 PM
Schlanger David J	Executive Chairman	Feb 01 '24	Sale	38.29	30,000	1,148,635	86,312	Feb 05 06:51 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	37.84	12,651	478,767	43,871	Feb 05 07:03 PM
Sturmer Michael E	PRESIDENT	Feb 01 '24	Sale	37.89	6,395	242,307	160,792	Feb 05 06:57 PM
Schlanger David J	Executive Chairman	Jan 08 '24	Option Exercise	3.95	66,002	261,005	152,314	Jan 10 06:31 PM
Schlanger David J	Executive Chairman	Jan 08 '24	Sale	37.88	66,002	2,500,156	86,312	Jan 10 06:31 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Jan 02 '24	Option Exercise	3.95	22,000	86,900	71,871	Jan 05 06:01 AM
Schlanger David J	Executive Chairman	Jan 02 '24	Option Exercise	3.95	13,998	55,355	102,437	Jan 04 06:30 PM
Schlanger David J	Executive Chairman	Jan 02 '24	Sale	37.58	13,998	526,024	88,439	Jan 04 06:30 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Jan 02 '24	Sale	36.59	12,368	452,540	46,871	Jan 05 06:01 AM
Sturmer Michael E	PRESIDENT	Jan 02 '24	Sale	36.81	6,395	235,400	167,187	Jan 04 06:42 PM
Schlanger David J	Executive Chairman	Dec 27 '23	Option Exercise	3.95	76,031	300,665	164,470	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 27 '23	Sale	37.66	76,031	2,863,525	88,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 26 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 26 '23	Sale	37.93	80,000	3,034,760	88,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 22 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 22 '23	Sale	38.11	80,000	3,048,408	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 21 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 21 '23	Sale	37.65	80,000	3,011,952	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 20 '23	Option Exercise	3.95	2,906	11,492	91,345	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 20 '23	Sale	37.50	2,906	108,987	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 14 '23	Option Exercise	3.95	1,063	4,204	89,502	Dec 18 07:39 PM
Schlanger David J	Executive Chairman	Dec 14 '23	Sale	37.53	1,063	39,894	88,439	Dec 18 07:39 PM
GORDON KEVIN K	Director	Dec 11 '23	Sale	35.93	2,500	89,825	9,854	Dec 13 07:06 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 01 '23	Option Exercise	3.95	44,000	173,800	102,377	Dec 05 07:44 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 01 '23	Sale	34.62	25,087	868,512	49,983	Dec 05 07:44 PM
Sturmer Michael E	PRESIDENT	Dec 01 '23	Sale	34.13	12,696	433,314	173,806	Dec 05 07:49 PM
TPG GP A, LLC	Former 10% Owner	Aug 07 '23	Sale	41.08	2,900,000	119,132,000	6,350,000	Aug 09 04:42 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Option Exercise	3.95	17,990	71,060	225,937	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Sale	38.95	17,990	700,710	207,947	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Sale	38.95	2,096	81,639	1	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Option Exercise	3.95	32,000	126,400	239,947	Jul 14 04:01 PM
Schlanger David J	Executive Chairman	Jul 13 '23	Option Exercise	0.91	67,457	61,386	138,263	Jul 14 04:02 PM
Schlanger David J	Executive Chairman	Jul 13 '23	Sale	38.95	67,457	2,627,450	70,806	Jul 14 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Sale	38.94	32,000	1,246,080	207,947	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Sale	38.94	8,000	311,520	2,097	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Option Exercise	3.95	23,572	93,109	231,519	Jul 14 04:01 PM
Schlanger David J	Executive Chairman	Jul 12 '23	Option Exercise	0.91	38,687	35,205	109,493	Jul 14 04:02 PM
Schlanger David J	Executive Chairman	Jul 12 '23	Sale	38.64	38,687	1,494,866	70,806	Jul 14 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Sale	38.64	23,572	910,822	207,947	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Sale	38.64	4,890	188,950	10,097	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Option Exercise	3.95	6,439	25,434	222,363	Jul 06 04:01 PM
Schlanger David J	Executive Chairman	Jul 03 '23	Option Exercise	0.91	18,856	17,159	92,343	Jul 06 04:02 PM
Schlanger David J	Executive Chairman	Jul 03 '23	Sale	38.76	18,856	730,859	73,487	Jul 06 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Sale	38.78	6,439	249,704	215,924	Jul 06 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Sale	38.78	1,610	62,436	14,987	Jul 06 04:01 PM
Scott Cheryl	Director	Jun 27 '23	Sale	37.27	1,170	43,606	9,744	Jul 07 05:15 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Sale	40.97	16,000	655,512	215,924	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Sale	40.97	4,000	163,878	16,597	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Sale	41.01	16,000	656,086	215,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Sale	41.01	4,000	164,021	20,597	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 07 06:22 PM
Schlanger David J	Executive Chairman	Jun 05 '23	Option Exercise	0.91	41,666	37,916	115,153	Jun 07 06:23 PM
Schlanger David J	Executive Chairman	Jun 05 '23	Sale	40.00	41,666	1,666,824	73,487	Jun 07 06:23 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Sale	40.00	16,000	640,057	215,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Sale	40.00	4,000	160,014	24,597	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 05 05:08 PM
Schlanger David J	Executive Chairman	Jun 02 '23	Option Exercise	0.91	41,667	37,917	115,154	Jun 05 04:48 PM
Schlanger David J	Executive Chairman	Jun 02 '23	Sale	38.68	41,667	1,611,680	73,487	Jun 05 04:48 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Sale	38.67	16,000	618,720	215,924	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Sale	38.67	4,000	154,680	28,597	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 05 05:08 PM
Schlanger David J	Executive Chairman	Jun 01 '23	Option Exercise	0.91	41,667	37,917	115,154	Jun 05 04:48 PM
Schlanger David J	Executive Chairman	Jun 01 '23	Sale	37.55	41,667	1,564,431	73,487	Jun 05 04:48 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Sale	37.55	16,000	600,850	215,924	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Sale	37.55	4,000	150,212	32,597	Jun 05 05:08 PM
GORDON KEVIN K	Director	May 24 '23	Sale	38.24	1,410	53,918	12,354	May 26 05:03 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Option Exercise	3.95	4,608	18,202	220,532	May 18 07:21 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Sale	35.94	4,608	165,612	215,924	May 18 07:21 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Sale	35.94	1,153	41,439	36,597	May 18 07:21 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 15 '23	Option Exercise	3.95	32,000	126,400	247,924	May 16 05:29 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 15 '23	Sale	36.24	32,000	1,159,680	215,924	May 16 05:29 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 15 '23	Sale	36.24	8,000	289,920	31,655	May 16 05:29 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 12 '23	Option Exercise	3.95	32,000	126,400	247,924	May 16 05:29 PM

Open in Screener

VCYT

Veracyte Inc

May 03 • 04:00PM ET

20.35

Dollar change +0.16
Percentage change 0.79	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN ARKW IBB

Index	RUT	P/E	-	EPS (ttm)	-1.02	Insider Own	1.67%	Shs Outstand	75.07M	Perf Week	5.39%
Market Cap	1.53B	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-1.57%	Shs Float	73.81M	Perf Month	0.89%
Income	-74.40M	PEG	-	EPS next Q	-0.16	Inst Own	104.38%	Short Float	4.93%	Perf Quarter	-18.04%
Sales	361.05M	P/S	4.23	EPS this Y	74.73%	Inst Trans	0.36%	Short Ratio	5.28	Perf Half Y	-3.37%
Book/sh	14.25	P/B	1.43	EPS next Y	84.39%	ROA	-6.40%	Short Interest	3.64M	Perf Year	-5.44%
Cash/sh	2.88	P/C	7.06	EPS next 5Y	-	ROE	-7.02%	52W Range	18.61 - 30.52	Perf YTD	-26.03%
Dividend Est.	-	P/FCF	44.59	EPS past 5Y	-10.52%	ROI	-7.08%	52W High	-33.32%	Beta	1.70
Dividend TTM	-	Quick Ratio	4.40	Sales past 5Y	34.42%	Gross Margin	61.81%	52W Low	9.35%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	4.66	EPS Y/Y TTM	-99.73%	Oper. Margin	-3.22%	RSI (14)	50.02	Volatility	4.94% 4.02%
Employees	815	Debt/Eq	0.01	Sales Y/Y TTM	21.76%	Profit Margin	-20.61%	Recom	1.89	Target Price	30.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-623.36%	Payout	-	Rel Volume	0.67	Prev Close	20.19
Sales Surprise	6.77%	EPS Surprise	-288.45%	Sales Q/Q	22.29%	Earnings	May 07 AMC	Avg Volume	689.13K	Price	20.35
SMA20	2.18%	SMA50	-4.33%	SMA200	-15.50%	Trades		Volume	463,335	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
03:20PM	Loading…
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
08:15AM	Loading…
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
09:00AM	Loading…
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Veracyte Announces First Quarter 2023 Financial Results (Business Wire)
09:45AM	New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules (Business Wire)
May-03-23 05:44PM	New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients (Business Wire)
08:30AM	Veracyte Announces Release of Inaugural ESG Report (Business Wire)
May-02-23 04:05PM	Data Published in "The Red Journal" Validate Clinical Utility of Veracytes Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer (Business Wire) -8.23%
May-01-23 05:35PM	Three Abstracts Focusing on the Clinical Utility of Veracytes Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference (Business Wire)
Apr-29-23 04:31PM	Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Apr-27-23 04:05PM	Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Business Wire)
10:02AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Apr-18-23 09:48AM	The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing (Simply Wall St.)
Apr-17-23 08:30AM	New Data Reinforce Ability of Veracytes Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Business Wire)
Apr-13-23 05:00PM	Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) +7.24%
Apr-12-23 08:30AM	Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Business Wire)
Mar-23-23 06:54AM	Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) (Simply Wall St.)
Mar-15-23 04:15PM	Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Companys Multi-Omics Capabilities and Tools for Biopharma Partners (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 12:11PM	Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank (Business Wire)
Mar-10-23 09:30AM	Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? (Motley Fool) -8.78%
Feb-27-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-23 05:42AM	We're Interested To See How Veracyte (NASDAQ:VCYT) Uses Its Cash Hoard To Grow (Simply Wall St.)
Feb-22-23 06:15PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.19%
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results (Business Wire)
Feb-15-23 08:36AM	Data Published in "The Red Journal" Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer (Business Wire)
Feb-13-23 05:23PM	New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment (Business Wire)
10:14AM	Stay Long and Strong: Billionaire Ken Fisher Snaps Up These 2 Strong Buy Stocks (TipRanks)
Feb-06-23 05:00PM	Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 (Business Wire)
Feb-01-23 04:05PM	Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
08:32AM	Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules (Business Wire)
Jan-24-23 10:23AM	Better Long-Term Buy in 2023: Exact Sciences or Veracyte? (Motley Fool)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire) +5.75%
Jan-18-23 06:10AM	This Small-Cap Stock Is a No-Brainer Buy (Motley Fool)
Dec-22-22 08:54AM	Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Dec-21-22 09:08AM	3 Medical Instruments Stocks on Recovery Path After Dismal 2022 (Zacks)
Dec-15-22 04:05PM	Data Published in JCEM Demonstrate Strong Real-World Performance of Veracytes Afirma GSC in Thyroid Cancer Diagnosis (Business Wire)
Dec-12-22 12:00PM	What Makes Veracyte (VCYT) a New Buy Stock (Zacks) +8.99%
Dec-01-22 02:46PM	Veracyte Stock Showing Market Leadership; Earns 93 RS Rating (Investor's Business Daily)
Nov-09-22 06:15AM	Veracyte Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) -7.49%
Nov-02-22 06:55PM	Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.57%
04:05PM	Veracyte Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-01-22 05:11PM	Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting (Business Wire)
Oct-27-22 05:00PM	Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference (Business Wire)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.17	3,090	93,232	35,173	Jul 24 05:06 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.14	838	25,257	37,601	Jul 24 05:06 PM
BISHOP JOHN L	Director	Jul 18 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
BISHOP JOHN L	Director	Jul 18 '23	Sale	30.50	10,000	305,000	33,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.19	7,441	224,616	38,263	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.16	2,324	70,090	38,439	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	23,949	720,106	45,704	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	19,095	574,106	40,763	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Sale	30.00	10,000	300,002	33,125	Jul 19 08:35 PM
Bhanji Muna	Director	Jun 16 '23	Sale	26.44	5,893	155,786	28,514	Jun 21 04:55 PM
Bhanji Muna	Director	May 30 '23	Sale	25.91	1,539	39,875	24,733	Jun 01 05:06 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PGNY

Progyny Inc

VCYT

Veracyte Inc

Upgrade your FINVIZ experience